Calidi Biotherapeutics, Inc.
CLDIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 21, 2024 | H.C. Wainwright | Robert Burns | $2.00(+233%) | $0.60 | StreetInsider |
| Oct 9, 2023 | Robert W. Baird | Joel Beatty | $9.00(-70%) | $29.80 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Baird | maintain | Outperform | May 15, 2024 |
| Baird | maintain | Outperform | Mar 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2024 |
Earnings History
Next report: Nov 17, 2026| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-2.94 | — | — | — |
| Mar 30, 2026 | $-6.88 | — | — | — |
| Mar 27, 2026 | $-9.12 | $-24.96 | — | — |
| Nov 11, 2025 | $-35.36 | $-26.88 | — | — |
| Aug 12, 2025 | $-31.84 | $-30.72 | — | — |
| May 13, 2025 | $-34.56 | $-28.80 | — | — |
| Apr 4, 2025 | $-51.84 | $-71.04 | — | — |
| Nov 12, 2024 | $-124.85 | $-164.26 | — | — |
News
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform generated approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors following IV delivery, without systemic administration of the TCE protein itself, turning the tumor into a localized TCE biofactory SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, I…
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. The presentations will showcase the Company's RedTail platform, a systemically delivered virotherapy platform engineered t…
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American C…
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company's common stock, in a registered direct offering, at a per share purchase price o…
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027